智擎生技製藥股份有限公司
智擎生技製藥股份有限公司（PharmaEngine, Inc.）在台灣從事癌症治療藥物的開發。其產品「ONIVYDE（安能得）」用於治療胰腺癌。目前正開發 PEP07（CHK1 抑制劑）用於血液腫瘤與實體瘤的臨床研究。公司成立於 2002 年，總部位於台灣台北。
今日下跌 1.26%，股價跌破短期均線。該股 RSI(6) 為 42.0，處於中性區間，短線無明顯超買超賣訊號。股價站上60日、120日均線，跌破5日、20日均線。KD 指標中性（K=65.9）；MACD 柱狀體為負值，空方動能持續。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-12 | +142 | 0 | +2 | +139 |
| 08-11 | -54 | 0 | 0 | -58 |
| 08-10 | +213 | 0 | +10 | +211 |
| 08-07 | +178 | 0 | +7 | +181 |
| 08-06 | -7 | 0 | 0 | -8 |
| 08-05 | -79 | 0 | +3 | -79 |
| 08-04 | +30 | 0 | +3 | +30 |
| 08-03 | +67 | 0 | +3 | +66 |
| 07-31 | -194 | 0 | +3 | -194 |
| 07-30 | +145 | 0 | +45 | +148 |
| 07-29 | +224 | 0 | +4 | +221 |
| 07-28 | +137 | 0 | +28 | +136 |
| 07-27 | -3 | 0 | 0 | -3 |
| 07-24 | +55 | 0 | +2 | +53 |
| 07-23 | -209 | +100 | +1 | -111 |
| 07-22 | +117 | 0 | +2 | +116 |
| 07-21 | +54 | 0 | +26 | +59 |
| 07-20 | +98 | 0 | +11 | +107 |
| 07-17 | +25 | 0 | 0 | +16 |
| 07-16 | -296 | 0 | +9 | -293 |
| 07-15 | +257 | 0 | +32 | +281 |
| 07-14 | +47 | 0 | +1 | +46 |
| 07-13 | +287 | 0 | +11 | +285 |
| 07-09 | +302 | 0 | +12 | +305 |
| 07-08 | -183 | +100 | +14 | -81 |
| 07-07 | +194 | 0 | +4 | +194 |
| 07-06 | -53 | 0 | +10 | -51 |
| 07-03 | +281 | 0 | +19 | +287 |
| 07-02 | -332 | 0 | +4 | -338 |
| 07-01 | +244 | 0 | +23 | +245 |
| 06-30 | +247 | 0 | +13 | +250 |
| 06-29 | +92 | 0 | +6 | +96 |
| 06-26 | +43 | 0 | +4 | +45 |
| 06-25 | -68 | 0 | +2 | -68 |
| 06-24 | +228 | 0 | +11 | +235 |
| 06-23 | +207 | 0 | +5 | +210 |
| 06-22 | -29 | 0 | +6 | -29 |
| 06-18 | +40 | 0 | 0 | +40 |
| 06-17 | -37 | 0 | +2 | -41 |
| 06-16 | -18 | 0 | +12 | -17 |
| 06-15 | -26 | 0 | 0 | -26 |
| 06-12 | +126 | 0 | +1 | +121 |
| 06-11 | -150 | 0 | +8 | -147 |
| 06-10 | +47 | 0 | +14 | +52 |
| 06-09 | +52 | 0 | +4 | +51 |
| 06-08 | +199 | 0 | +5 | +199 |
| 06-05 | +196 | 0 | +4 | +197 |
| 06-04 | +21 | 0 | +4 | -20 |
| 06-03 | -128 | 0 | 0 | -128 |
| 06-02 | +118 | 0 | +2 | +120 |
| 06-01 | +169 | 0 | +2 | +165 |
| 05-29 | +273 | 0 | 0 | +272 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 2401 萬 | -84.5% | -2.1% |
| 2026/03 | 1.55 億 | +1080.9% | +6.0% |
| 2026/02 | 1308 萬 | -81.9% | -28.1% |
| 2026/01 | 7219 萬 | -68.3% | +208.3% |
| 2025/12 | 2.27 億 | +657.6% | -87.6% |
| 2025/11 | 3003 萬 | +8.9% | +29.9% |
| 2025/10 | 2757 萬 | -86.0% | +24.7% |
| 2025/09 | 1.98 億 | +790.1% | +18.4% |
| 2025/08 | 2220 萬 | -0.7% | -14.7% |
| 2025/07 | 2236 萬 | -85.5% | -11.9% |
| 2025/06 | 1.54 億 | +729.4% | -0.2% |
| 2025/05 | 1854 萬 | - | -78.6% |